Biocorrx Inc (PK:BICX)
Business Focus: Healthcare Facilities & Services
| Sector: Healthcare | Industry: Healthcare Facilities & Services |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 2390 East Orangewood Avenue, Suite 500 ANAHEIM CA 92806 |
| Tel: | N/A |
| Website: | https://www.biocorrx.com |
| IR: | See website |
| Key People | ||
| Louis C. Lucido President, Director | Lourdes Felix Chief Executive Officer, Chief Financial Officer, Director | Thomas Patrick Welch Executive Vice President |
| Business Overview |
| BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. Its BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained-release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Biocorrx Inc revenues decreased 58% to $89K. Net loss decreased 14% to $3.8M. Revenues reflect Project support income segment decrease of 83% to $26K, Distribution rights income segment decrease of 11% to $33K. Lower net loss reflects Research and development decrease of 39% to $891K (expense), Selling, general and administrative decrease of 16% to $2.9M (expense). |
| Employees: | 5 as of Dec 31, 2011 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $14.86M as of Dec 31, 2023 |
| Annual revenue (TTM): | $0.09M as of Dec 31, 2023 |
| EBITDA (TTM): | -$3.71M as of Dec 31, 2023 |
| Net annual income (TTM): | -$3.77M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$1.85M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $1.61M as of Dec 31, 2023 |
| Shares outstanding: | 8,815,454 as of Mar 29, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.